Correlation of Response between Both Eyes to First- and Second-Line Anti-VEGF Therapy in Diabetic Macular Edema

References

• Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The wisconsin epidemiologic study of diabetic retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16. doi:10.1016/S0161-6420(95)31052-4.
   PubMed Web of Science ®Google Scholar
• Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, Selvin E, Dolan C, Fine J, Colman S, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–40. doi:10.1001/jamaophthalmol.2014.2854.
   PubMed Web of Science ®Google Scholar
• Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletchr A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Feb 04;35(3):556–64. doi:10.2337/dc11-1909.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008 Jul 30;115(9):1447–9, 1449 e1-10.
   Web of Science ®Google Scholar
• Kohly RP, Muni RH, Kertes PJ. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular EDEMA. Evidence-Based Ophthalmol. 2010;11(4):199–201. doi:10.1016/j.ophtha.2010.02.031.
   Google Scholar
• Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14. doi:10.1016/j.ophtha.2010.12.033.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, et al. Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, et al. The restore study. Ophthalmology. 2011;118(4):615–25. doi:10.1016/j.ophtha.2011.01.031.
   PubMed Web of Science ®Google Scholar
• Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54. doi:10.1016/j.ophtha.2014.05.006.
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044–52. doi:10.1016/j.ophtha.2015.06.017.
   PubMed Web of Science ®Google Scholar
• Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema. Curr Opin Ophthalmol. 2017;28(6):636–43. [accessed 2015 Feb 19] http://insights.ovid.com/crossref?an=00055735-201711000-00016.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Frederick FL, Hampton GR, Chiraget J, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–59. doi:10.1016/j.ophtha.2016.02.022.
   PubMed Web of Science ®Google Scholar
• Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, Siqueira RC, Scott IU, Messias A, Jorge R. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013 Jun 26;156(3):502–10 e2. doi:10.1016/j.ajo.2013.04.026.
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018 Jan;136(1):29–38. doi:10.1001/jamaophthalmol.2017.4914.
   PubMed Web of Science ®Google Scholar
• Hanhart J, Tiosano L, Averbukh E, Banin E, Hemo I, Chowers I. Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye (Lond). 2014 Jun;28(6):646–53. doi:10.1038/eye.2014.94.
   PubMed Web of Science ®Google Scholar
• Khatri A, Karki P, Joshi SN, Kharel Sitaula R. Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema. BMJ Open Ophthalmol. 2017;2(1):e000102. doi:10.1136/bmjophth-2017-000102.
   PubMed Web of Science ®Google Scholar
• Guillard M, Dupas B, El Sanharawi M, Erginay A, Tadayoni R, Massin P. Symmetry in early response to intravitreal ranibizumab in bilateral diabetic macular oedema. Acta Ophthalmol. 2016 Aug;94(5):e356–60. doi:10.1111/aos.12905.
   PubMed Web of Science ®Google Scholar
• Krick TW, Bressler NM. Recent clinically relevant highlights from the diabetic retinopathy clinical research network. Curr Opin Ophthalmol. 2018;29(3):199–205. doi:10.1097/ICU.0000000000000472.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells J 3rd. A persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018 Feb 03;136(3):257–69. doi:10.1001/jamaophthalmol.2017.6565.
   PubMed Web of Science ®Google Scholar
• Karth PA, Chang A, Wirostko W. Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye. Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):207–11. doi:10.1007/s00417-013-2422-4.
   PubMed Web of Science ®Google Scholar